Check out which companies are making headlines after the bell Thursday:
CBS - Shares dropped after the television network reported disappointing revenue. The media firm said it earned 78 cents per share, which beat expectations, but revenue fell to $3.19 billion, missing Street expectations of $3.24 billion.
Lululemon - The stock rallied after its founder, Chip Wilson, agreed to sell half of his stake in company to private equity firm Advent. As a part of the the $845 million deal, he agreed not to launch a proxy war on the yoga-gear producer.
News Corp - The company earned 1 cent per share, missing expectations by 2 cents, but revenue came in at $2.19 billion, beating expectations for $2.17 billion. Shares edged higher after hours.
Nvidia - The maker of PC graphic chips reported profit and sales that were in line with estimates, sending the stock higher in after-hours trading. The company earned 22 cent per share on revenue of $1.10 billion, beating analysts' forecast of 20 cents EPS on $1.10 billion in sales.
Zynga - The game maker's shares plunged after it reported net profit broke, in line with estimates, while revenue came in at $175 million, missing expectations for $191 million in booking revenue. Moreover, the company lowered its full-year guidance to reflect the product launch delays.
Monster Beverage - The maker of energy drinks reported mixed second-quarter earnings and revenue. Net sales for the second-quarter rose about 9 percent to $687 million, missing Street estimates of $694 million, while earnings came in at 81 cents per share, reflecting a beat of 6 cents. Shares rose slightly after the announcement.
Lionsgate - The film and entertainment firm topped earnings expectations, but revenue trailed. Lionsgate earned 27 cents per share on $449 million, versus expectations of 18 cents per share on $489 million. Shares gained in extended hours trading.
Tekmira Pharmaceuticals - The stock rallied after the firm announced the that Food and Drug Administration had modified a clinical hold placed on its Ebola drug. The move enables the pharma company to potentially use of the treatment on individuals infected with Ebola virus.
—By CNBC's Karma Allen
Questions? Comments? Email us at email@example.com